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ABSTRACT
A large number of novel secondary sulfonamides based on the open saccharin scaffold were synthesized
and evaluated as selective inhibitors of four different isoforms of human carbonic anhydrase (hCA I, II, IX
and XII, EC 4.2.1.1). They were obtained by reductive ring opening of the newly synthesized N-alkylated
saccharin derivatives and were shown to be inactive against the two cytosolic off-target hCA I and II
(Kis> 10mM). Interestingly, these compounds inhibited hCA IX in the low nanomolar range with Kis ranging
between 20 and 298 nM and were extremely potent inhibitors of hCA XII isoenzyme (Kis ranging between
4.3 and 432nM). Since hCA IX and XII are the cancer-related isoforms recently validated as drug targets,
these results represent an important goal in the development of new anticancer candidates. Finally, a com-
putational approach has been performed to better correlate the biological data to the binding mode of
these inhibitors.
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Introduction
Carbonic anhydrases are a vast family of metalloenzymes (CAs, EC
4.2.1.1.) strongly involved in regulating cell homeostasis and intra-
cellular pH by catalyzing the reversible hydration of carbonic diox-
ide to bicarbonate ions1. Fifteen human isoforms are discovered to
date and can be differentiated on the basis of cellular localization,
tissue distribution, catalytic activity and affinity to various inhibi-
tors, thus representing validated therapeutic targets for the treat-
ment of a wide range of diseases2,3. In particular, hCA IX and XII
were identified as part of the complex machinery that primary and
metastatic cancer cell lines use to compensate their dysregulated
pH in poorly vascularized microenvironments, like the surround-
ings of solid tumours4–6. Targeting these cancer-related isoforms
has attracted a lot of attention, hence leading to the proliferation
of literature on the subject and the development of structurally
diverse inhibitors7–19. As a result of this superb effort, a potent
hCA IX selective compound (SLC-0111) is currently in Phase I clin-
ical trials for the treatment of solid metastatic tumors, conse-
quently boosting the research for new suitable candidates20,21.
Since the active site of CAs is characterized by the presence of
a catalytic zinc ion hold in place by three histidine residues, one
of the most successful approaches to design novel CAIs implies
introducing a zinc-binding group (ZBG) in the scaffold of potential
inhibitors22. In fact, the most widely prescribed CAIs are character-
ized by the presence of a primary sulfonamide group, which
efficiently engages the positively charged zinc ion upon deproto-
nation23–26. However, despite primary sulfonamides being pre-
ferred “zinc binding group”, they are usually associated with
promiscuous profiles and lack of selectivity amongst the different
isoforms. On the other side, secondary and tertiary sulfonamides
have been lately reported in the literature as efficient and select-
ive inhibitors of the cancer-related hCA IX and XII isoforms27–31,
although their binding mode remains a subject of investigation32.
In a recent publication, Ivanova et al. reported on the spontaneous
ring opening of cyclic tertiary sulfonamides under basic (pH¼ 9)
crystallization conditions33. Since hCAs do not possess any peptid-
ase activity, they concluded that the base-catalyzed hydrolysis of
the saccharin isothiazolone ring happened before the inhibitor
entered the active site, and proved their hypothesis by testing
both open and closed analogs against a panel of hCAs (hCA I,
hCA II, hCA IX and hCA XII). In particular, these open saccharin
derivatives determined an increased inhibition of hCA IX, while
retaining high activity against hCA II. Such promising results
prompted us to investigate the effects of ring opening on our pre-
viously reported N-substituted saccharins as selective inhibitors of
CA IX and XII15,34. In this paper, we used a reductive ring opening
approach to induce the 5-membered isothiazolone ring of sac-
charin to collapse into its corresponding secondary sulfonamide
and benzyl alcohol (Figure 1)35. The rationale behind this choice
could be found in the opportunity of generating two new poten-
tial anchoring points for the zinc ion, while introducing several
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degrees of freedom to the bonds connecting the two hydrophobic
phenyl substituents to the polar core of the molecule. In general,
the newly synthesized compounds (1–21) proved to be as potent
as or slightly less potent than parent inhibitors, while the selectiv-
ity for the cancer-related isoforms (hCA IX and XII) over the off-tar-
get hCA I and II improved dramatically. In fact, none of the
reported compounds inhibited hCA I and II isoforms at concentra-
tions lower than 10 mM, while Ki values spanned from 20 to
298 nM against hCA IX and from 4.3 to 382 nM against hCA XII.
Chemistry
Saccharin (1.0 eq.) was activated using freshly ground anhydrous
potassium carbonate and the corresponding salt was then directly
reacted with a proper electrophile (2 eq. of substituted benzyl
halide or a-haloacetophenone) by stirring the reaction mixture in
N,N-dimethylformamide at 80 C overnight (Scheme 1). Following
these optimized conditions (polar aprotic solvent), we strictly
obtained only the more stable regioisomers (N-substituted
saccharin derivatives) limiting the Chapman–Mumm thermal
rearrangement to the less stable O-substituted counterparts36.
N-substituted saccharin derivatives were then subjected to reduc-
tive ring opening with an excess of NaBH4 in dry methanol at
room temperature for 2–8 h to give the corresponding secondary
sulfonamide compounds 1–21 in discrete yields following a previ-
ously reported procedure with slight modifications35.
Our choice of NaBH4 as a reducing agent depended on prelim-
inary experiments which suggested that (i) the sulfone group was
not affected by these mild reducing conditions leading to the car-
bonyl group reduction to the alcohol level only with saccharin
ring cleavage and that (ii) similar results were obtained for the
preparation of o-hydroxymethyl-N-alkyl-benzamides starting from
N-alkyl-phthalimides37.
In their IR spectra, we usually registered for the open saccharin
derivatives new but expected signals for the OH and NH stretch-
ing at 3240 and 3470 cm1, respectively, and the disappearance of
the C¼O stretching at 1735 cm1.
Biological evaluation
All the synthesized compounds were tested to evaluate their
inhibitory activity towards the ubiquitous off-target isoforms,
hCA I and II, and the cancer-related ones, hCA IX and XII, by a
stopped-flow, CO2 hydrase assay method and their CA inhibition
data (Ki) are summarized in Table 1.
Experimental protocols
General
Solvents and reagents were used as supplied without further puri-
fication. Where mixtures of solvents are specified, the stated ratios
are volume:volume. Acetazolamide was purchased by Sigma-
Aldrich (Italy) and used in the biological assays without further
purification. All synthesized compounds have been fully character-
ized by analytical and spectral data. Column chromatography was
carried out using Sigma-AldrichVR silica gel (high-purity grade, pore
size 60Å, 200–425 mesh particle size). Analytical thin-layer chro-
matography was carried out on Sigma-AldrichVR silica gel on TLA
aluminum foils with fluorescent indicator. Visualization was carried
out under UV irradiation (254 nm). 1H-NMR spectra were recorded
on a Bruker AV400 (1H: 400MHz, 13C: 101MHz). 19F-NMR spectra
were recorded on a Bruker AVANCE 600 spectrometer (19F:
564.7MHz). Chemical shifts are quoted in ppm, based on appear-
ance rather than interpretation, and are referenced to the residual
non deuterated solvent peak. In the case of 19F, chemical shifts
 
Figure 1. Reductive ring opening approach to the synthesis of novel CAIs.
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Scheme 1. Synthesis and structure of compounds 1–21. For R substituents see Table 1.
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are referenced to an external standard (CF3COOH, d 76.55 ppm).
Infrared spectra were recorded on a Bruker Tensor 27 FTIR spec-
trometer equipped with an attenuated total reflectance attach-
ment with internal calibration. Absorption maxima (max) are
reported in wavenumbers (cm1). All melting points were meas-
ured on a StuartVR melting point apparatus SMP1 and are uncor-
rected. Temperatures are reported in C. Where given, systematic
compound names are those generated by ChemBioDraw UltraVR
12.0 following IUPAC conventions. NMR spectra for some represen-
tative compounds could be found in the Supplementary material.
Procedures for the synthesis of the new open saccharin
derivatives
2-(Hydroxymethyl)-N-(2-methylbenzyl)benzenesulfonamide (1)
(2-Methylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.)
was suspended in 20mL of anhydrous methanol at room tempera-
ture. An excess of NaBH4 was added portionwise and the reaction
monitored by TLC. After 2 h the reaction was quenched with water
and the aqueous phase was extracted with dichloromethane
(3 30mL). The organic layers were reunited, dried over sodium
sulfate, and concentrated in vacuo to give a crude product which
was purified by column chromatography (EtOAc/n-hexane, 1:4).
The title compound was a white solid (52% yield); mp 64–66 C; IR
max 3459 ( O–H), 3237 ( N–H), 3065 ( Csp2–H), 1319 (as S¼O),
1167 (s S¼O), 712 (d Csp2–H) cm1; 1H-NMR (400MHz, CDCl3) d
2.25 (s, 3H, CH3), 2.77 (bs, 1H, OH, D2O exch.), 4.08 (s, 2H, CH2),
5.01 (s, 2H, CH2), 5.43 (bs, 1H, NH, D2O exch.), 7.09–7.19 (m, 4H,
CHAr), 7.47–7.61 (m, 3H, CHAr), 8.01–8.04 (m, 1H, CHAr);
13C-NMR
(101MHz, CDCl3) d 18.7 (CH3), 45.5 (CH2), 64.2 (CH2), 126.2 (Ar),
128.2 (Ar), 128.5 (Ar), 128.9 (Ar), 129.6 (Ar), 129.9 (Ar), 130.5 (Ar),
131.6 (Ar), 133.2 (Ar), 134.1 (Ar), 136.6 (Ar), 138.2 (Ar).
2-(Hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)benzenesulfona-
mide (2)
(2-Trifluoromethylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide
(1.0 eq.) was suspended in 20mL of anhydrous methanol at room
temperature. An excess of NaBH4 was added portionwise and the
reaction monitored by TLC. After 4 h the reaction was quenched
with water and the aqueous phase was extracted with dichlorome-
thane (3 30mL). The organic layers were reunited, dried over
sodium sulfate, and concentrated in vacuo to give a crude product
that was purified by column chromatography (EtOAc/n-hexane,
1:3). The title compound was a white solid (47% yield); mp
66–68 C; IR max 3446 ( O–H), 3214 ( N–H), 1310 (as S¼O),
1157 (s S¼O), 714 (d Csp2–H) cm1; 1H-NMR (400MHz, CDCl3) d
2.81 (t, 1H, J¼ 5.4 Hz, OH, D2O exch.), 4.17 (d, 2H, J¼ 6.0 Hz, CH2),
4.91 (s, 2H, CH2), 5.83 (m, 1H, NH, D2O exch.), 7.27 (t, 1H,
J¼ 7.6 Hz, CHAr), 7.35–7.41 (m, 3H, CHAr), 7.46–7.50 (m, 3H, CHAr),
7.89–7.91 (m, 1H, CHAr);
13C-NMR (101MHz, CDCl3) d 43.7 (CH2),
63.9 (CH2), 124.2 (C-F,
1JC-F¼274.8 Hz, CF3), 125.9 (Ar), 126.0 (Ar),
127.9 (Ar), 128.6 (Ar), 129.7 (Ar), 130.6 (Ar), 131.6 (Ar), 132.3 (Ar),
133.3 (Ar), 135.0 (Ar), 138.0 (Ar), 138.1 (Ar); 19F-NMR (564.7MHz,
CDCl3) d -56.89 (s, CF3).
2-(Hydroxymethyl)-N-(2-nitrobenzyl)benzenesulfonamide (3)
(2-Nitrobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.)
was suspended in 20mL of anhydrous methanol at room tempera-
ture. An excess of NaBH4 was added portionwise and the reaction
monitored by TLC. After 6 h the reaction was quenched with water
and the aqueous phase was extracted with dichloromethane
(3 30mL). The organic layers were reunited, dried over sodium
sulfate, and concentrated in vacuo to give the title compound as a
light brown solid (37% yield); mp 103–105 C; IR max 3498 (
O–H), 3238 ( N–H), 2973 ( Csp3–H), 1522 ( N–O), 1327 (as
S¼O), 1165 (s S¼O), 698 (d Csp2–H) cm1; 1H-NMR (400MHz,
DMSO-d6) d 4.34 (d, 2H, J¼ 5.6 Hz, CH2), 4.88 (s, 2H, CH2), 5.45 (bs,
1H, OH, D2O exch.), 7.39 (t, 1H, J¼ 7.2 Hz, CHAr), 7.50 (t, 1H,
J¼ 7.6 Hz, CHAr), 7.60–7.68 (m, 3H, 3 x CHAr), 7.74–7.79 (m, 2H, 2 
CHAr), 7.96 (d, 1H, J¼ 8.4 Hz, CHAr), 8.29 (bs, 1H, NH, D2O exch.);
13C-NMR (101MHz, DMSO-d6) d 43.4 (CH2), 60.0 (CH2), 125.1 (Ar),
127.3 (Ar), 128.2 (Ar), 128.5 (Ar), 129.1 (Ar), 130.7 (Ar), 133.0 (Ar),
133.4 (Ar), 134.1 (Ar), 137.0 (Ar), 141.6 (Ar), 148.1 (Ar).
N-(2-bromobenzyl)-2-(hydroxymethyl)benzenesulfonamide (4)
(2-Bromobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.)
was suspended in 20mL of anhydrous methanol at room tempera-
ture. An excess of NaBH4 was added portionwise and the reaction
monitored by TLC. After 6 h the reaction was quenched with water
and the aqueous phase was extracted with dichloromethane
(3 30mL). The organic layers were reunited, dried over sodium
sulfate, and concentrated in vacuo to give a crude product which
was purified by column chromatography (EtOAc/n-hexane, 2:1).
The title compound was a white solid (0.05 g, 11% yield); mp
162–164 C; IR max 3273 ( O–H and  N–H), 2920 ( Csp3–H),
1402 (as S¼O), 1065 (s S¼O), 676 (d Csp2–H) cm1; 1H-NMR
(400MHz, CDCl3) d 3.45 (bs, 1H, OH, D2O exch.), 4.14 (d, 2H,
J¼ 6.4 Hz, CH2), 4.93 (s, 2H, CH2), 6.18 (m, 1H, NH, D2O exch.), 7.03
(t, 1H, J¼ 7.6 Hz, CHAr), 7.15 (t, 1H, J¼ 7.4 Hz, CHAr), 7.28 (d, 1H,
J¼ 6.8 Hz, CHAr), 7.33–7.49 (m, 4H, CHAr), 7.87 (d, 1H, J¼ 8.0 Hz,
CHAr);
13C-NMR (101MHz, CDCl3) d 47.4 (CH2), 63.5 (CH2), 123.4
(Ar), 127.6 (Ar), 128.3 (Ar), 129.4 (Ar), 129.6 (Ar), 130.3 (Ar), 131.3
(Ar), 132.7 (Ar), 133.1 (Ar), 135.6 (Ar), 137.8 (Ar), 138.4 (Ar).
2-(Hydroxymethyl)-N-(3-methylbenzyl)benzenesulfonamide (5)
(3-Methylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.)
was suspended in 20mL of anhydrous methanol at room tempera-
ture. An excess of NaBH4 was added portionwise and the reaction
monitored by TLC. After 7 h the reaction was quenched with water
and the aqueous phase was extracted with dichloromethane
(3 30mL). The organic layers were reunited, dried over sodium sul-
fate, and concentrated in vacuo to give a crude product which was
purified by column chromatography (EtOAc/n-hexane, 1:4). The title
compound was a white solid (51% yield); mp 79–80 C; IR max 3431
( O–H), 3161 ( N–H), 2936 ( Csp3–H), 1316 (as S¼O), 1152 (s
S¼O), 694 (d Csp2–H) cm1; 1H-NMR (400MHz, CDCl3) d 2.27 (s, 3H,
CH3), 2.80 (bs, 1H, OH, D2O exch.), 4.07 (bs, 2H, CH2), 4.99 (s, 2H,
CH2), 5.72 (bs, 1H, NH, D2O exch.), 6.96 (d, 2H, J¼ 7.6 Hz, CHAr), 7.04
(d, 1H, J¼ 8.0 Hz, CHAr), 7.14 (t, 1H, J¼ 7.4 Hz, CHAr), 7.44–7.49 (m,
2H, CHAr), 7.55–7.59 (m, 1H, CHAr), 7.98 (d, 1H, 7.8 Hz, CHAr);
13C-NMR
(101MHz, CDCl3) d 21.3 (CH3), 47.5 (CH2), 63.8 (CH2), 124.9 (Ar), 128.4
(Ar), 128.5 (Ar), 128.6 (Ar), 128.7 (Ar), 129.8 (Ar), 131.5 (Ar), 133.1 (Ar),
136.1 (Ar), 138.1 (Ar), 138.2 (Ar), 138.3 (Ar).
2-(Hydroxymethyl)-N-(3-(trifluoromethyl)benzyl)benzenesulfona-
mide (6)
(3-Trifluoromethylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide
(1.0 eq.) was suspended in 20mL of anhydrous methanol at room
temperature. An excess of NaBH4 was added portionwise and the
reaction monitored by TLC. After 8 h the reaction was quenched
with water and the aqueous phase was extracted with dichlorome-
thane (3 30mL). The organic layers were reunited, dried over
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sodium sulfate, and concentrated in vacuo to give a crude product
which was purified by column chromatography (EtOAc/n-hexane,
1:3). The title compound was a white solid (71% yield); mp
76–78 C; IR max 3430 ( O–H), 3278 ( N–H), 1317 (as S¼O),
1160 (s S¼O), 700 (d Csp2–H) cm1; 1H-NMR (400MHz, CDCl3) d
2.98 (t, 1H, J¼ 4.8 Hz, OH, D2O exch.), 4.06 (d, 2H, J¼ 6.4 Hz, CH2),
4.91 (d, 2H, J¼ 4.0 Hz, CH2), 6.07 (m, 1H, NH, D2O exch.), 7.24–7.37
(m, 6H, CHAr), 7.42–7.46 (m, 1H, CHAr), 7.82 (d, 1H, J¼ 7.6 Hz, CHAr);
13C-NMR (101MHz, CDCl3) d 46.9 (CH2), 63.9 (CH2), 123.9 (C-F,
1JC-
F¼273.4Hz, CF3), 124.5 (Ar), 124.6 (Ar), 128.6 (Ar), 129.1 (Ar), 129.7
(Ar), 130.7 (Ar), 131.3 (Ar), 131.7 (Ar), 133.3 (Ar), 137.4 (Ar), 137.8
(Ar), 138.0 (Ar); 19F-NMR (564.7MHz, CDCl3) d -60.09 (s, CF3).
2-(Hydroxymethyl)-N-(3-nitrobenzyl)benzenesulfonamide (7)
(3-Nitrobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.)
was suspended in 20mL of anhydrous methanol at room tempera-
ture. Excess of NaBH4 was added portionwise and the reaction
monitored by TLC. After 6 h the reaction was quenched with water
and the aqueous phase was extracted with dichloromethane
(3 30mL). The organic layers were reunited, dried over sodium
sulfate, and concentrated in vacuo to give a crude product that
was purified by column chromatography (EtOAc/n-hexane, 2:1).
The title compound was a white solid (37% yield); mp 109–111 C;
IR max 3491 ( O–H), 3164 ( N–H), 2958 ( Csp3–H), 1536 ( N–O),
1326 (as S¼O), 1162 (s S¼O), 695 (d Csp2–H) cm1; 1H-NMR
(400MHz, DMSO-d6) d 4.16 (s, 2H, CH2), 4.87 (s, 2H, CH2), 5.47 (bs,
1H, OH, D2O exch.), 7.33–7.37 (m, 1H, CHAr), 7.51–7.60 (m, 2H,
CHAr), 7.64 (d, 1H, J¼ 7.6 Hz, CHAr), 7.73–7.75 (m, 2H, CHAr), 8.04 (s,
1H, CHAr), 8.06 (s, 1H, CHAr), 8.35 (bs, 1H, NH, D2O exch.);
13C-NMR
(101MHz, DMSO-d6) d 45.4 (CH2), 59.9 (CH2), 122.5 (Ar), 122.6 (Ar),
127.1 (Ar), 127.9 (Ar), 128.5 (Ar), 130.2 (Ar), 132.9 (Ar), 134.6 (Ar),
137.2 (Ar), 140.8 (Ar), 141.5 (Ar), 148.1 (Ar).
N-(3-fluorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (8)
(3-Fluorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.)
was suspended in 20mL of anhydrous methanol at room tempera-
ture. An excess of NaBH4 was added portionwise and the reaction
monitored by TLC. After 5 h the reaction was quenched with water
and the aqueous phase was extracted with dichloromethane
(3 30mL). The organic layers were reunited, dried over sodium
sulfate, and concentrated in vacuo to give a crude product which
was purified by column chromatography (EtOAc/n-hexane, 1:1).
The title compound was a light yellow oil (67% yield); IR max
3492 ( O–H), 3283 ( N–H), 2895 ( Csp3–H), 1318 (as S¼O), 1252
( Csp2–F), 1175 (s S¼O), 689 (d Csp2–H) cm1; 1H-NMR (400MHz,
CDCl3) d 2.84 (bs, 1H, OH, D2O exch.), 4.05 (s, 2H, CH2), 4.97 (s, 2H,
CH2), 6.04 (bs, 1H, NH, D2O exch.), 6.85–6.94 (m, 3H, CHAr),
7.17–7.20 (m, 1H, CHAr), 7.39–7.55 (m, 3H, CHAr), 7.92 (d, 1H,
J¼ 7.6 Hz, CHAr); 13C-NMR (101MHz, CDCl3) d 46.6 (CH2), 63.6
(CH2), 114.6 (Ar-F,
2JC-F¼ 21.1 Hz), 114.8 (Ar-F, 2JC-F¼ 22.0 Hz), 123.4
(Ar-F, long-rangeJC-F¼ 2.7 Hz), 128.5 (Ar), 129.7 (Ar), 130.1 (Ar-F,
3JC-F¼ 8.2 Hz), 131.6 (Ar), 133.2 (Ar), 137.9 (Ar), 138.1 (Ar), 139.0
(Ar-F, 3JC-F¼ 7.3 Hz), 162.7 (Ar-F, 1JC-F¼ 247.45Hz); 19F-NMR
(564.7MHz, CDCl3) d -110.03 (ddd, JF-H¼ 9.5 Hz, 8.6 Hz, 5.2 Hz, CF).
N-(3-bromobenzyl)-2-(hydroxymethyl)-benzenesulfonamide (9)
(3-Bromobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.)
was suspended in 20mL of anhydrous methanol at room tempera-
ture. An excess of NaBH4 was added portionwise and the reaction
monitored by TLC. After 5 h the reaction was quenched with water
and the aqueous phase was extracted with dichloromethane
(3 30mL). The organic layers were reunited, dried over sodium
sulfate, and concentrated in vacuo to give a crude product which
was purified by column chromatography (EtOAc/n-hexane, 1:1).
The title compound was a white solid (70% yield); mp 75–76 C; IR
max 3454 ( O–H), 3214 ( N–H), 2955 ( Csp3–H), 1319 (as S¼O),
1156 (s S¼O), 694 (d Csp2-H) cm1; 1H-NMR (400MHz, DMSO-d6) d
4.00 (d, 2H, J¼ 6Hz, CH2), 4.87 (d, 2H, J¼ 5.2 Hz, CH2), 5.42 (bs, 1H,
OH, D2O exch.), 7.20 (bs, 2H, CHAr), 7.38 (bs, 3H, CHAr), 7.59–7.63
(m, 1H, CHAr), 7.75–7.78 (m, 2H, CHAr), 8.23 (bs, 1H, NH, D2O exch.);
13C-NMR (101MHz, DMSO-d6) d 45.6 (CH2), 59.9 (CH2), 122.0 (Ar),
127.0 (Ar), 127.2 (Ar), 127.9 (Ar), 128.5 (Ar), 130.4 (Ar), 130.7 (Ar),
130.8 (Ar), 132.9 (Ar), 137.2 (Ar), 141.2 (Ar), 141.5 (Ar).
2-(Hydroxymethyl)-N-(4-methylbenzyl)benzenesulfonamide (10)
(4-Methylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.)
was suspended in 20mL of anhydrous methanol at room tempera-
ture. An excess of NaBH4 was added portionwise and the reaction
monitored by TLC. After 6 h the reaction was quenched with water
and the aqueous phase was extracted with dichloromethane
(3 30mL). The organic layers were reunited, dried over sodium
sulfate, and concentrated in vacuo to give a crude product which
was purified by column chromatography (EtOAc/n-hexane, 1:4).
The title compound was a white solid (56% yield); mp 100–102 C;
IR max 3437 ( O–H), 3130 ( N–H), 2930 ( Csp3–H), 1310 (as
S¼O), 1151 (s S¼O), 701 (d Csp2-H) cm1; 1H-NMR (400MHz,
CDCl3) d 2.31 (s, 3H, CH3), 2.80 (bs, 1H, OH, D2O exch.), 4.07 (d, 2H,
J¼ 5.2 Hz, CH2), 4.99 (s, 2H, CH2), 5.60 (bs, 1H, NH, D2O exch.), 7.06
(bs, 4H, CHAr), 7.44–7.50 (m, 2H, CHAr), 7.55–7.60 (m, 1H, CHAr),
8.00 (d, 1H, 7.6 Hz, CHAr);
13C-NMR (101MHz, CDCl3) d 21.1 (CH3),
47.3 (CH2), 63.8 (CH2), 127.9 (Ar), 128.5 (Ar), 129.3 (Ar), 129.9 (Ar),
131.6 (Ar), 133.1 (Ar), 133.2 (Ar), 137.6 (Ar), 138.1 (Ar), 138.2 (Ar).
2-(Hydroxymethyl)-N-(4-(trifluoromethyl)benzyl)benzenesulfona-
mide (11)
(4-Trifluoromethylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide
(1.0 eq.) was suspended in 20mL of anhydrous methanol at room
temperature. An excess of NaBH4 was added portionwise and the
reaction monitored by TLC. After 8 h the reaction was quenched
with water and the aqueous phase was extracted with dichlorome-
thane (3 30mL). The organic layers were reunited, dried over
sodium sulfate, and concentrated in vacuo to give a crude product
which was purified by column chromatography (EtOAc/n-hexane,
1:3). The title compound was a white solid (79% yield); mp
78–80 C; IR max 3417 ( O–H), 3161 ( N-H), 3065 ( Csp2–H), 1321
(as S¼O), 1157 (s S¼O), 688 (d Csp2–H) cm1; 1H-NMR (400MHz,
CDCl3) d 3.03 (bs, 1H, OH, D2O exch.), 4.15 (d, 2H, J¼ 6.4 Hz, CH2),
5.02 (d, 2H, J¼ 5.2 Hz CH2), 6.14 (t, 1H, J¼ 6.4 Hz, NH, D2O exch.),
7.32 (d, 2H, J¼ 8.0 Hz, CHAr), 7.40–7.49 (m, 4H, CHAr), 7.54–7.58 (m,
1H, CHAr), 7.91 (s, 1H, CHAr);
13C-NMR (101MHz, CDCl3) d 46.9 (CH2),
63.9 (CH2), 124.0 (C-F,
1JC-F¼ 273.1Hz, CF3), 125.4 (Ar), 125.5 (Ar),
128.1 (Ar), 128.6 (Ar), 129.7 (Ar), 129.8 (Ar), 130.1 (Ar), 131.7 (Ar),
133.3 (Ar), 137.8 (Ar), 138.0 (Ar), 140.4 (Ar); 19F-NMR (564.7MHz,
CDCl3) d -60.08 (s, CF3).
N-(4-cyanobenzyl)-2-(hydroxymethyl)benzenesulfonamide (12)
(4-Cyanobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.)
was suspended in 20mL of anhydrous methanol at room tempera-
ture. An excess of NaBH4 was added portionwise and the reaction
monitored by TLC. After 8 h the reaction was quenched with water
and the aqueous phase was extracted with dichloromethane
(3 30mL). The organic layers were reunited, dried over sodium
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sulfate and concentrated in vacuo to give a crude product, which
was purified by column chromatography (EtOAc/n-hexane, 2:1).
The title compound was a white solid (67% yield); mp 93–95 C; IR
max 3481 ( O–H), 3187 ( N–H), 2949 ( Csp3–H), 2235 CN, 1325
(as S¼O), 1156 (s S¼O), 703 (d Csp2–H) cm1; 1H-NMR (400MHz,
DMSO-d6) d 4.09 (s, 2H, CH2), 4.88 (s, 2H, CH2), 5.46 (bs, 1H, OH,
D2O exch.), 7.35–7.41 (m, 3H, CHAr), 7.59–7.62 (m, 1H, CHAr),
7.70–7.77 (m, 4H, CHAr), 8.33 (bs, 1H, NH, D2O exch.);
13C-NMR
(101MHz, DMSO-d6) d 45.9 (CH2), 59.9 (CH2), 110.3 (Ar), 119.3 (CN),
127.2 (Ar), 127.9 (Ar), 128.5 (Ar), 128.7 (Ar), 132.6 (Ar), 132.9 (Ar),
137.1 (Ar), 141.6 (Ar), 144.3 (Ar).
2-(Hydroxymethyl)-N-(4-nitrobenzyl)benzenesulfonamide (13)
(4-Nitrobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.)
was suspended in 20mL of anhydrous methanol at room tempera-
ture. An excess of NaBH4 was added portionwise and the reaction
monitored by TLC. After 8 h the reaction was quenched with water
and the aqueous phase was extracted with dichloromethane
(3 30mL). The organic layers were reunited, dried over sodium
sulfate, and concentrated in vacuo to give a crude product, which
was purified by column chromatography (EtOAc/n-hexane, 1:1).
The title compound was a yellow solid (57% yield); mp 98–99 C;
IR max 3493 ( O–H), 3243 ( N–H), 1515 ( N–O), 1318 (as S¼O),
1160 (s S¼O), 690 (d Csp2-H) cm1; 1H-NMR (400MHz, CDCl3) d
2.74 (bs, 1H, OH, D2O exch.), 4.21 (bs, 2H, CH2), 5.08 (s, 2H, CH2),
6.13 (bs, 1H, NH, D2O exch.), 7.40–7.59 (m, 5H, CHAr), 7.96–7.97 (m,
1H, CHAr), 8.11–8.13 (m, 2H, CHAr);
13C-NMR (101MHz, CDCl3) d
46.7 (CH2), 64.3 (CH2), 123.7 (Ar), 128.5 (Ar), 128.8 (Ar), 129.8 (Ar),
131.6 (Ar), 133.4 (Ar), 137.6 (Ar), 138.7 (Ar), 144.0 (Ar), 147.2 (Ar).
N-(4-fluorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (14)
(4-Fluorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.)
was suspended in 20mL of anhydrous methanol at room tempera-
ture. An excess of NaBH4 was added portionwise and the reaction
monitored by TLC. After 8 h the reaction was quenched with water
and the aqueous phase was extracted with dichloromethane (3 x
30mL). The organic layers were reunited, dried over sodium sul-
fate, and concentrated in vacuo to give a crude product which
was purified by column chromatography (EtOAc/n-hexane, 1:3).
The title compound was a light brown solid (79% yield); mp
99–100 C; IR max 3439 ( O–H), 3140 ( N–H), 1312 (as S¼O),
1151 (s S¼O), 696 (d Csp2-H) cm1; 1H-NMR (400MHz, CDCl3) d
3.18 (bs, 1H, OH, D2O exch.), 4.04 (d, 2H, J¼ 6.4 Hz, CH2), 4.98 (s,
2H, CH2), 6.00 (bs, 1H, NH, D2O exch.), 6.88–6.93 (m, 2H, CHAr),
7.12–7.15 (m, 2H, CHAr), 7.41–7.57 (m, 3H, CHAr), 7.93 (d, 1H,
J¼ 8.0 Hz, CHAr); 13C-NMR (101MHz, CDCl3) d 46.7 (CH2), 63.7
(CH2), 115.4 (Ar-F,
2JC-F¼21.2 Hz), 128.5 (Ar), 129.6 (Ar), 129.7 (Ar),
131.6 (Ar), 132.0 (Ar), 132.1 (Ar), 133.2 (Ar), 138.0 (Ar), 138.1 (Ar),
135.4 (Ar-F, 1JC-F¼247.3 Hz); 19F-NMR (564.7MHz, CDCl3) d -111.71
(tt, JF-H¼ 8.7 Hz (ortho), 5.3 Hz (meta), CF).
N-(4-chlorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (15)
(4-Chlorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq)
was suspended in 20mL of anhydrous methanol at room tempera-
ture. An excess of NaBH4 was added portionwise and the reaction
monitored by TLC. After 7 h the reaction was quenched with water
and the aqueous phase was extracted with dichloromethane
(3 30mL). The organic layers were reunited, dried over sodium
sulfate, and concentrated in vacuo to give a crude product which
was purified by column chromatography (EtOAc/n-hexane, 1:1).
The title compound was a white solid (70% yield); mp 103–105 C;
IR max 3458 ( O–H), 3236 ( N–H), 2876 ( Csp3–H), 1314 (as
S¼O), 1152 (s S¼O), 690 (d Csp2–H) cm1; 1H-NMR (400MHz,
CDCl3) d 2.90 (bs, 1H, OH, D2O exch.), 4.06 (d, 2H, J¼ 6.0 Hz, CH2),
5.01 (s, 2H, CH2), 5.88 (bs, 1H, NH, D2O exch.), 7.11 (d, 2H,
J¼ 8.4 Hz, CHAr), 7.21 (d, 2H, J¼ 8.4 Hz, CHAr), 7.43–7.49 (m, 2H,
CHAr), 7.56–7.60 (m, 1H, CHAr), 7.95 (d, 1H, J¼ 7.6 Hz, CHAr); 13C-
NMR (101MHz, CDCl3) d 46.8 (CH2), 63.9 (CH2), 128.6 (Ar), 128.7
(Ar), 129.3 (Ar), 129.8 (Ar), 131.6 (Ar), 133.2 (Ar), 133.7 (Ar), 134.8
(Ar), 137.9 (Ar), 138.1 (Ar).
N-(4-bromobenzyl)-2-(hydroxymethyl)benzenesulfonamide (16)
(4-Bromobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.)
was suspended in 20mL of anhydrous methanol at room tempera-
ture. An excess of NaBH4 was added portionwise and the reaction
monitored by TLC. After 7 h the reaction was quenched with water
and the aqueous phase was extracted with dichloromethane
(3 30mL). The organic layers were reunited, dried over sodium
sulfate, and concentrated in vacuo to give a crude product which
was purified by column chromatography (EtOAc/n-hexane, 1:2).
The title compound was a white solid (53% yield); mp 124–125 C;
IR max 3461 ( O–H), 3234 ( N–H), 3064 ( Csp2–H), 1314 (as
S¼O), 1152 (s S¼O), 690 (d Csp2–H) cm1; 1H-NMR (400MHz,
CDCl3) d 2.71 (bs, 1H, OH, D2O exch.), 4.06 (bs, 2H, CH2), 5.03 (s,
2H, CH2), 5.78 (bs, 1H, NH, D2O exch.), 7.06–7.08 (m, 2H, CHAr),
7.37–7.59 (m, 5H, CHAr), 7.96–7.97 (m, 1H, CHAr);
13C-NMR
(101MHz, CDCl3) d 46.9 (CH2), 64.1 (CH2), 121.9 (Ar), 128.6 (Ar),
129.6 (Ar), 129.8 (Ar), 131.7 (Ar), 133.2 (Ar), 137.9 (Ar), 138.3 (Ar).
N-(2,6-difluorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (17)
(2,6-Difluorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0
eq.) was suspended in 20mL of anhydrous methanol at room tem-
perature. An excess of NaBH4 was added portionwise and the
reaction monitored by TLC. After 7 h the reaction was quenched
with water and the aqueous phase was extracted with dichlorome-
thane (3 30mL). The organic layers were reunited, dried over
sodium sulfate, and concentrated in vacuo to give a crude product
which was purified by column chromatography (EtOAc/n-hexane,
1:1). The title compound was a white solid (67% yield); mp
128–130 C; IR max 3495 ( O–H), 3159 ( N–H), 2958 ( Csp3–H),
1320 (as S¼O), 1159 (s S¼O), 693 (d Csp2–H) cm1; 1H-NMR
(400MHz, CDCl3) d 2.72 (bs, 1H, OH, D2O exch.), 4.23 (s, 2H, CH2),
4.89 (bs, 2H, CH2), 6.04 (bs, 1H, NH, D2O exch.), 6.79–6.73 (m, 2H,
CHAr), 7.10–7.14 (m, 1H, CHAr), 7.26 (s, 1H, CHAr), 7.33–7.48 (m, 2H,
CHAr), 7.92–7.94 (m, 1H, CHAr);
13C-NMR (101MHz, CDCl3) d 35.1
(CH2), 63.6 (CH2), 111.2 (Ar-F,
2JC-F¼ 24.8 Hz), 128.3 (Ar), 129.7 (Ar),
129.9 (Ar), 130.0 (Ar), 130.1 (Ar), 131.2 (Ar), 133.1 (Ar), 137.8 (Ar),
138.2 (Ar), 161.2 (Ar-F, 1JC-F¼ 246.9 Hz); 19F-NMR (564.7MHz,
CDCl3) d -112.08 (t, JF-H¼ 6.9 Hz, CF).
N-(3,4-dichlorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (18)
(3,4-Chlorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.)
was suspended in 20mL of anhydrous methanol at room tempera-
ture. An excess of NaBH4 was added portionwise and the reaction
monitored by TLC. After 7 h the reaction was quenched with water
and the aqueous phase was extracted with dichloromethane
(3 30mL). The organic layers were reunited, dried over sodium
sulfate, and concentrated in vacuo to give a crude product which
was purified by column chromatography (EtOAc/n-hexane, 2:1).
The title compound was a light brown solid (81% yield); mp
83–84 C; IR max 3463 ( O–H), 3192 ( N–H), 2947 ( Csp3–H),
1319 (as S¼O), 1158 (s S¼O), 690 (d Csp2–H) cm1; 1H-NMR
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(400MHz, CDCl3) d 2.88 (bs, 1H, OH, D2O exch.), 3.96 (d, 2H,
J¼ 6.4 Hz, CH2), 4.93 (bs, 2H, CH2), 6.00 (t, 1H, J¼ 6.0 Hz NH, D2O
exch.), 6.94–6.96 (bs, 1H, CHAr), 7.17–7.22 (m, 2H, CHAr), 7.33–7.39
(m, 2H, CHAr), 7.46–7.48 (m, 1H, CHAr), 7.83 (d, 1H, J¼ 7.6 Hz, CHAr);
13C-NMR (101MHz, CDCl3) d 46.3 (CH2), 64.0 (CH2), 127.2 (Ar),
128.6 (Ar), 129.7 (Ar), 129.8 (Ar), 130.5 (Ar), 131.7 (Ar), 131.8 (Ar),
132.6 (Ar), 133.3 (Ar), 136.7 (Ar), 137.7 (Ar), 138.1 (Ar).
2-(Hydroxymethyl)-N-(naphthalen-1-ylmethyl)benzenesulfonamide
(19)
2-(Naphthalen-1-ylmethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide
(1.0 eq.) was suspended in 20mL of anhydrous methanol at room
temperature. An excess of NaBH4 was added portionwise and the
reaction monitored by TLC. After 6 h the reaction was quenched
with water and the aqueous phase was extracted with dichlorome-
thane (3 30mL). The organic layers were reunited, dried over
sodium sulfate, and concentrated in vacuo to give a crude product
which was purified by column chromatography (EtOAc/n-hexane,
1:1). The title compound was a white solid (57% yield); mp
80–81 C; IR max 3517 ( O–H), 3347 ( N–H), 3061 ( Csp2–H),
1318 (as S¼O), 1157 (s S¼O), 690 (d Csp2–H) cm1; 1H-NMR
(400MHz, CDCl3) d 2.68 (bs, 1H, OH, D2O exch.), 4.51 (s, 2H, CH2),
4.91 (s, 2H, CH2), 5.69 (bs, 1H, NH, D2O exch.), 7.29–7.55 (m, 7H,
CHAr), 7.74–7.86 (m, 3H, CHAr), 8.05 (s, 1H, CHAr);
13C-NMR
(101MHz, CDCl3) d 45.6 (CH2), 63.7 (CH2), 123.2 (Ar), 125.2 (Ar),
126.0 (Ar), 126.6 (Ar), 127.0 (Ar), 128.4 (Ar), 128.7 (Ar), 129.0 (Ar),
130.0 (Ar), 131.1 (Ar), 131.4 (Ar), 131.5 (Ar), 133.2 (Ar), 133.7 (Ar),
137.6 (Ar), 138.3 (Ar).
N-(2-hydroxy-2-phenylethyl)-2-(hydroxymethyl)benzenesulfonamide
(20)
2-(2-Oxo-2-phenylethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide
(1.0 eq.) was suspended in 20mL of anhydrous methanol at room
temperature. An excess of NaBH4 was added portionwise and the
reaction monitored by TLC. After 8 h the reaction was quenched
with water and the aqueous phase was extracted with dichlorome-
thane (3 30mL). The organic layers were reunited, dried over
sodium sulfate, and concentrated in vacuo to give a crude product
which was purified by column chromatography (EtOAc/n-hexane,
2:1). The title compound was a light yellow oil (49% yield); IR max
3291 ( O–H and  N–H), 2923 ( Csp3–H), 1316 (as S¼O), 1153
(s S¼O), 696 (d Csp2–H) cm1; 1H-NMR (400MHz, CDCl3) d 2.94
(bs, 1H, CH2), 3.15 (bs, 1H, CH2), 3.42 (bs, 1H, OH, D2O exch.),
4.56–4.64 (m, 2H, CH2), 4.91–5.03 (m, 1H, CH), 5.28 (bs, 1H, OH,
D2O exch.), 6.57 (bs, 1H, NH, D2O exch.), 7.13–7.20 (m, 5H, CHAr),
7.38–7.47 (m, 3H, CHAr), 7.91 (d, 1H, J¼ 6.4 Hz, CHAr); 13C NMR
(101MHz, CDCl3) d 50.4 (CH2), 62.7 (CH2), 72.4 (CH), 125.8 (Ar),
127.9 (Ar), 128.2 (Ar), 128.5 (Ar), 129.5 (Ar), 131.3 (Ar), 133.3 (Ar),
137.3 (Ar), 138.6 (Ar), 140.8 (Ar).
N-(2-hydroxy-2-(3-methoxyphenyl)ethyl)-2-(hydroxymethyl)benze-
nesulfonamide (21)
2-(2-Hydroxy-2-(3-methoxyphenyl)ethyl)benzo[d]isothiazol-3(2H)-
one 1,1-dioxide (1.0 eq.) was suspended in 20mL of anhydrous
methanol at room temperature. An excess of NaBH4 was added
portionwise and the reaction monitored by TLC. After 8 h the reac-
tion was quenched with water and the aqueous phase was
extracted with dichloromethane (3 30mL). The organic layers
were reunited, dried over sodium sulfate, and concentrated in
vacuo to give a crude product which was purified by column chro-
matography (EtOAc/n-hexane, 1:2). The title compound was a yel-
low oil (88% yield); IR max 3477 ( O–H), 3295 ( N–H), 2935 (
Csp3–H), 1317 (as S¼O), 1160 (s S¼O), 697 (d Csp2–H) cm1; 1H-
NMR (400MHz, CDCl3) d 2.89–2.95 (m, 1H, CH2), 3.13–3.17 (m, 1H,
CH2), 3.64 (s, 3H, OCH3), 4.41 (bs, 2H, CH2), 4.58 (bs, 1H, OH),
4.87–4.91 (m, 1H, CH), 4.97 (bs, 1H, OH, D2O exch.), 6.48 (bs, 1H,
NH, D2O exch.), 6.67–6.71 (m, 3H, CHAr), 7.07–7.11 (m, 1H, CHAr),
7.32–7.47 (m, 3H, CHAr), 7.87 (d, 1H, J¼ 7.6 Hz, CHAr); 13C-NMR
(101MHz, CDCl3) d 50.4 (CH2), 55.1 (OCH3), 60.6 (CH2), 72.2 (CH),
111.4, (Ar), 113.3 (Ar), 118.1 (Ar), 128.2 (Ar), 129.5 (Ar), 129.6
(Ar), 131.2 (Ar), 133.2 (Ar), 137.3 (Ar), 138.6 (Ar), 142.5 (Ar), 159.5
(ArO).
Enzyme inhibition assays
An applied photophysics stopped-flow instrument has been used
for assaying the CA-catalyzed CO2 hydration activity. Phenol red
(0.2mM) has been used as indicator, working at the absorbance
maximum of 557 nm, with 20mM Hepes (pH 7.5, for a-CAs) as buf-
fer, and 20mM NaClO4 (for maintaining constant the ionic
strength), following the initial rates of the CA-catalyzed CO2 hydra-
tion reaction for a period of 10–100 s. The CO2 concentrations
ranged from 1.7 to 17mM for the determination of the kinetic
parameters and inhibition constants. For each inhibitor at least six
traces of the initial 5–10% of the reaction have been used for
determining the initial velocity. The uncatalyzed rates were deter-
mined in the same manner and subtracted from the total
observed rates. Stock solutions of each inhibitor (1mM) were pre-
pared in distilled-deionized water and dilutions up to 0.1 nM were
done thereafter with the assay buffer. Inhibitor and enzyme solu-
tions were preincubated together for 15min at room temperature
prior to assay, in order to allow for the formation of the E-I com-
plex or for the eventual active site mediated hydrolysis of the
inhibitor. The inhibition constants were obtained by non-linear
least-squares methods using PRISM 3 and the Cheng–Prusoff
equation, and represent the average from at least three different
determinations. All recombinant CA isoforms were obtained in-
house as previously reported38,39.
Molecular modeling studies
Preparation of saccharin-based structures
The saccharin-based analogs 1–21 were prepared in 3D with the
MOE software package (v2013.08.02, Chemical Computing Group
Inc., Montreal, Canada) as previously reported40. All possible struc-
tural isomers of compounds were constructed. Strong acids were
deprotonated and strong bases were protonated. Finally, the
ligands were energy minimized using a steepest-descent protocol
(MMFF94x force field).
Preparation of hCA crystal structures for docking studies
The structures of hCA I (PDB: 3LXE, 1.90 Å), hCA II (PDB: 4E3D,
1.60 Å), hCA IX (PDB: 3IAI, 2.20 Å) and hCA XII (PDB: 1JD0, 1.50 Å)
were obtained from the protein databank (PDB). The protein
atoms, the active site zinc ions and the zinc-bound water molecule
of hCA II were retained and all other atoms were omitted. The
remaining structure was protonated using the MOE software pack-
age and subsequently the obtained structure was energy-mini-
mized (AMBER99 force field). Finally, the obtained protein models
were superposed on the hCA I structure using the backbone Ca-
atoms. The zinc-bound water molecule of hCA II coordinated well
to the zinc ions of the other hCAs.
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Docking studies
The GOLD Suite software package (v5.2, CCDC, Cambridge, UK)
and the GoldScore scoring function were used to dock the deriva-
tives into the hCA structures with and without the zinc-bound
water molecule (25 dockings per ligand). The binding pocket was
defined as all residues within 13Å of a centroid (x: 17.071, y:
35.081, 43.681; corresponding approximately to the position of the
thiadiazole ring of acetazolamide in the 1JD0 structure).
Results and discussion
The analysis of the biological data was accomplished comparing
the open saccharin-based derivatives with their corresponding par-
ent compounds in order to evaluate if the ring opening enhanced
or reduced their biological activity.
All the tested compounds had no affinity for the common off-
target hCA I and II isoforms (Kis> 10000 nM) compared to their
corresponding parent drugs. Moreover, our molecules with a ben-
zyl alcohol group, instead of a carboxylic acid33, abolished com-
pletely this inhibitory activity improving the biological profile of
this scaffold.
The inhibition profile of the open saccharin-based derivatives
against the two tumor-related hCA IX and XII isoforms also dis-
played some important changes compared to parent drugs.
Among the new open saccharin derivatives reported here, the
best activity was obtained toward hCA XII isoform by compounds
1, 5, 6, 10 and 11, all provided of CH3 or CF3 groups. These mole-
cules exhibited a slightly preference for hCA XII respect to hCA IX
isoform, although the inhibition of the latter was also in the nano-
molar range. Compound 5, containing a phenyl ring substituted
with methyl group in meta position, had the highest inhibitory
activity against hCA XII (Ki¼ 4.3 nM), but also compound 6, con-
taining a meta trifluoromethyl substituent on phenyl ring, exhib-
ited similar inhibitory activity (Ki¼ 4.4 nM). Comparable profile
against hCA XII was observed for compounds 10 (Ki¼ 5.7 nM) and
11 (Ki¼ 7.2 nM), which are para substituted regioisomers of 5 and
6, respectively. Compound 1, which had a methyl group at ortho
position of phenyl ring, showed similar inhibitory activity (Ki hCA
XII¼ 4.7 nM) with respect to 5 and 6. Other compounds with
strong selectivity between hCA IX and XII were 9 (Ki hCA
IX¼ 267 nM, Ki hCA XII¼ 64 nM) with bromine in meta position of
phenyl ring, 12 (Ki hCA IX¼ 126 nM, Ki hCA XII¼ 57 nM) containing
a cyano group in para position, 15 (Ki hCA IX¼ 154 nM, Ki hCA
XII¼ 48 nM) which had a para chloro-substituted phenyl ring, 17
and 18 with, respectively, 2,6-difluoro and 3,4-dichloro-substituted
phenyl rings.
Conversely, some compounds displayed a good selectivity
towards hCA IX isoform. Compounds with nitro substituents in
ortho (3), meta (7) or para (13) position of the ring had potent
inhibitory activity preferentially against this overexpressed isoform
in the hypoxic tumoral niche.
For compounds 20 (Ki hCA IX¼ 224 nM, Ki hCA XII¼ 64 nM) and
21 (Ki hCA IX¼ 31 nM, Ki hCA XII¼ 355 nM), the reaction with
NaBH4 led to the further reduction of exocyclic carbonyl moiety.
The presence of this additional group maintained the biological
profile with a loss of inhibitory activity against hCA I and II and a
preferential selectivity against the cancer-related isoforms.
Collectively, these promising data showed that the reductive
ring opening of the saccharin nucleus improved the hCA inhibitory
activity with a better selectivity with respect to the off-target iso-
forms. From the above, we also observed that the inhibition pro-
file was affected positively or negatively by the substitution
pattern.
Docking studies into the active site of hCA XII
The open saccharin analogs (compounds 1–21) were endowed
with inhibition values in the nanomolar range against hCA XII iso-
form (Ki values: 4.3–432 nM, Table 1, approximately 100-fold differ-
ence between lowest and highest Ki values). The interaction of
compound 6 with the active site of hCA XII was shown as an
example (Figure 2). Docking studies indicated that the hydroxy-
methyl group and one of the sulfonamide oxygen atoms could
interact simultaneously with the Zn2þ-ion, whereas the other sul-
fonamide oxygen atom was water accessible. This oxygen might
also form hydrogen bonds with the backbone of Thr199. The
other polar substituents of the molecule were water accessible.
Conclusion
We proposed the design, synthesis, characterization and pharma-
cological evaluation in vitro of several new secondary sulfonamides
based on the open saccharin scaffold as selective inhibitors of four
different isoforms of human carbonic anhydrase. They were shown
to be inactive against the two cytosolic off-target hCA I and II
(Kis> 10mM); conversely, all these compounds inhibited hCA IX
and XII in the low nanomolar range with Kis ranging between 4.3
and 432nM. The analysis of the Ki values showed as the substituent
on phenyl moiety that gives the best outcomes relative to inhib-
ition of hCA XII isoform are methyl and trifluoromethyl groups.
Table 1. Inhibitory activity of the open saccharin-based derivatives 1–21 and
acetazolamide as a reference drug, against selected hCA isoforms by a stopped-
flow CO2 hydrase assay.
HN
OH
R
O2
S
Compound R Ki (nM)
hCA I hCA II hCA IX hCA XII
1 2-CH3 >10000 >10000 218 4.6
2 2-CF3 >10000 >10000 200 54
3 2-NO2 >10000 >10000 104 383
4 2-Br >10000 >10000 113 323
5 3-CH3 >10000 >10000 223 4.3
6 3-CF3 >10000 >10000 238 4.4
7 3-NO2 >10000 >10000 176 382
8 3-F >10000 >10000 268 247
9 3-Br >10000 >10000 267 64
10 4-CH3 >10000 >10000 120 5.7
11 4-CF3 >10000 >10000 253 7.2
12 4-CN >10000 >10000 126 57
13 4-NO2 >10000 >10000 20 54
14 4-F >10000 >10000 26 63
15 4-Cl >10000 >10000 154 48
16 4-Br >10000 >10000 145 432
17 2,6-diF >10000 >10000 296 45
18 3,4-diCl >10000 >10000 298 40
19 2,3-Phenylene >10000 >10000 294 345
HN
OH
O2
S
HO R
20 H >10000 >10000 224 64
21 3-OCH3 >10000 >10000 31 355
AAZ (acetazolamide) 250 12 25 6.0
Mean from 3 different assays (errors were in the range of ±5–10% of the
reported values).
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The results were also rationalized by means of docking studies
into the active site of hCA XII. Since these two cancer-related hCA
isoforms were recently validated as drug targets, these results pro-
vided the development of new anticancer candidates.
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